S. Saxer (Zürich, Switzerland), G. Kovacs (Graz, Austria)
Study of a novel hypoxia system to evaluate endothelial cell dysfunction in chronic thromboembolic pulmonary hypertension (CTEPH)
Y. Roger (Barcelona, Spain), I. Almendros (Barcelona, Spain), E. Marhuenda (Barcelona, Spain), A. Bosacoma (Barcelona, Spain), A. Sardiné (Barcelona, Spain), À. Vea (Barcelona, Spain), A. Ramírez (Barcelona, Spain), V. Peinado (Barcelona, Spain), I. Blanco (Barcelona, Spain), M. Castellà (Barcelona, Spain), J. Barberà (Barcelona, Spain), O. Tura (Girona, Spain)
|   |
MicroRNA expression in Chronic Thromboembolic Pulmonary Hypertension
I. Opitz (Zurich, Switzerland), T. Papasotiropoulos (Zurich, Switzerland), I. Martínez López (Zurich, Switzerland), F. Schläpfer (Zurich, Switzerland), S. Ulrich (Zurich, Switzerland), M. Kirschner (Zurich, Switzerland)
| |
Pulmonary Hypertension (PH) due to Pulmonary Embolism (PE) secondary to COVID19 – A District General Hospital (DGH) experience from the UK
I. Nadeem (Luton, United Kingdom), N. Mahdi (Luton, United Kingdom), M. Ur Rasool (Bury St Edmunds, United Kingdom), S. Radoja (Luton, United Kingdom), F. Rashad (Luton, United Kingdom), A. Babu (Luton, United Kingdom), N. Mahdi (London, United Kingdom)
| |
Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension improves sleep-disordered breathing
K. Hackner (Krems, Austria), C. Gerges (Vienna, Austria), S. Bauer (Vienna, Austria), M. Kneussl (Vienna, Austria), P. Errhalt (Krems, Austria), S. Javaheri (Cincinnati, United States), I. Lang (Vienna, Austria)
| |
Right atrial pressure to pulmonary artery wedge pressure ratio in chronic thromboembolic pulmonary hypertension
A. Yogeswaran (Giessen, Germany), K. Tello (Giessen, Germany), S. Kaufmann (Giessen, Germany), N. Sommer (Giessen, Germany), Z. Rako (Giessen, Germany), H. Ghofrani (Giessen, Germany), W. Seeger (Giessen, Germany), M. Richter (Giessen, Germany), H. Gall (Giessen, Germany)
| |
Carbon dioxide and alveolar dead space as prognostic markers for pulmonary endarterectomy patients
K. Furrer (Zürich, Switzerland), J. Welsch (Zürich, Switzerland), D. Bettex (Zürich, Switzerland), T. Horisberger (Zürich, Switzerland), I. Inci (Zürich, Switzerland), R. Schuepbach (Zürich, Switzerland), M. Kirschner (Zürich, Switzerland), S. Ulrich (Zürich, Switzerland), A. Matter (Zürich, Switzerland), I. Opitz (Zürich, Switzerland)
| |
Pulmonary thromboendarterectomy after COVID-19 infection: USA single center experience
A. Bautista (La Jolla, United States), M. Madani (La Jolla, United States), V. Pretorius (La Jolla, United States), J. Yang (La Jolla, United States), T. Fernandes (La Jolla, United States), D. Papamatheakis (La Jolla, United States), D. Poch (La Jolla, United States), K. Kerr (La Jolla, United States), N. Kim (La Jolla, United States)
| |
Medical bridging therapy before pulmonary endarterectomy?
D. Jenkins (Cambridge, United Kingdom), J. Pepke-Zaba (Cambridge, United Kingdom), E. Fadel (Paris, France), G. Simonneau (Paris, France), N. Kim (San Diego, United States), M. Madani (San Diego, United States), H. Matsubara (Okayama, Japan), M. Delcroix (Leuven, Belgium), I. Lang (Vienna, Austria), E. Mayer (Bad Nauheim, Germany)
| |
Evaluation of chronic thromboembolic pulmonary hypertension: a pilot-study
B. Ruaro (Trieste, Italy), P. Confalonieri (Trieste, Italy), G. Caforio (Trieste, Italy), C. Torregiani (Trieste, Italy), P. Geri (Trieste, Italy), R. Pozzan (Trieste, Italy), S. Pichierri (Trieste, Italy), M. Confalonieri (Trieste, Italy), F. Salton (Trieste, Italy)
| |
Remodeling of small airways and their associated vasculature is a hallmark of Idiopathic Pulmonary Fibrosis.
A. Moran-MacDonald (Kingston, Canada), K. Wu (Vancouver, Canada), K. Ikezoe (Vancouver, Canada), S. Ledoux (Vancouver, Canada), J. Cooper (Philapelphia, United States), J. Hogg (Vancouver, Canada), D. Vasilescu (Vancouver, Canada), T. Hackett (Vancouver, Canada)
| |
Acute vasoreactivity in WSPH Group-3 pulmonary hypertension and relation to inhaled treprostinil response
E. Harder (Boston, United States), D. Systrom (Boston, United States), A. Waxman (Boston, United States)
| |
Clinical phenotypes and outcomes of severe pulmonary hypertension associated with chronic obstructive pulmonary disease
D. Montani (Paris, France), A. Diaz (Saint Etienne Cedex, France), S. Chelabi (Paris, France), X. Jais (Paris, France), L. Savale (Paris, France), M. Froudarakis (Saint Etienne Cedex, France), S. Bezzeghoud (Saint Etienne Cedex, France), A. Boucly (Paris, France), M. Jevnikar (Paris, France), O. Sitbon (Paris, France), L. Bertoletti (Saint Etienne Cedex, France), M. Humbert (Paris, France)
| |
Recognition of early pulmonary structural changes with real-time high fidelity expiratory CO2 analysis
T. Sassmann (Medical University of Graz, Department of Internal Medicine, Division of Pulmonology, Austria), M. Pienn (Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria), G. Kovacs (Medical University of Graz, Department of Internal Medicine, Division of Pulmonology, Austria), P. Douschan (Medical University of Graz, Department of Internal Medicine, Division of Pulmonology, Austria), V. Foris (Medical University of Graz, Department of Internal Medicine, Division of Pulmonology, Austria), N. John (Medical University of Graz, Department of Internal Medicine, Division of Pulmonology, Austria), K. Zeder (Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria), A. Zirlik (Medical University of Graz, Department of Internal Medicine, Division of Cardiology, Austria), H. Olschewski (Medical University of Graz, Department of Internal Medicine, Division of Pulmonology, Austria)
| |
Efficacy of Digoxin in isolated Right ventricular Dysfunction due to Chronic Pulmonary Diseases
S. Pothal (Puri, India), N. Tengli (Burla, Odisha, India), N. Patel (Burla, Odisha, India), A. Behera (Burla, Odisha, India)
| |
Hemodynamic mechanisms in patients with pulmonary hypertension and chronic obstructive pulmonary disease: a retrospective monocentric cohort study
P. Thoré (Nancy, France), J. Staentzel (Nancy, France), S. Valentin (Nancy, France), A. Guillaumot (Nancy, France), C. Selton-Suty (Nancy, France), E. Gomez (Nancy, France), F. Chabot (Nancy, France), A. Chaouat (Nancy, France), A. Chaouat (Vandoeuvre-Les-Nancy, France)
| |
Pulmonary Vascular Calcification As A Pathomechanism In Pulmonary Hypertension Due To Left Heart Disease
S. Liu (Berlin, Germany), . Kucherenko (Berlin, Germany), P. Sang (Berlin, Germany), Q. Li (Berlin, Germany), J. Yao (Berlin, Germany), N. Nambiar Veetil (Berlin, Germany), T. Gransar (Berlin, Germany), . Alesutan (Linz, Austria), J. Voelk (Linz, Austria), C. Knosalla (Berlin, Germany), W. Kuebler (Berlin, Germany)
| |
Right ventricle – pulmonary artery coupling is a risk factor for mortality in patients with pulmonary hypertension associated with heart failure and preserved ejection fraction
S. Nazzal (Poriya, Lower Galilee15208, Israel), S. Carasso (Jerusalem, Israel), C. Simsolo (Poriya, Lower Galilee15208, Israel), M. Amara (Poriya, Lower Galilee15208, Israel), Y. Adir (Haifa, Israel)
| |
The effect of parenchymal lung disease on patient characteristics and outcome in SSc-PH: Insights from the ASPIRE registry
A. Haque (Sheffield (South Yorkshire), United Kingdom), K. Divwedi (Sheffield (South Yorkshire), United Kingdom), R. Lewis (Sheffield (South Yorkshire), United Kingdom), A. Charalampopoulos (Sheffield (South Yorkshire), United Kingdom), C. Elliot (Sheffield (South Yorkshire), United Kingdom), A. Hameed (Sheffield (South Yorkshire), United Kingdom), N. Hamilton (Sheffield (South Yorkshire), United Kingdom), S. Ramjug (Sheffield (South Yorkshire), United Kingdom), A. Rothman (Sheffield (South Yorkshire), United Kingdom), A. Swift (Sheffield (South Yorkshire), United Kingdom), R. Thompson (Sheffield (South Yorkshire), United Kingdom), D. Kiely (Sheffield (South Yorkshire), United Kingdom), R. Condliffe (Sheffield (South Yorkshire), United Kingdom)
| |
Pulmonary hypertension and ECG synchronized CT scan for pulmonary artery pulsatility calculation in pre-TAVI patients and prognostic significance
J. Khoury (New Haven, United States), I. Naoum (Haifa, Israel), Y. Shachaf (Haifa, Israel), M. Qdah (Haifa, Israel), R. Yaffi (Haifa, Israel), Y. Adir (Haifa, Israel)
| |
Right ventricular myocardial dysfunction in patients (pts) after severe coronavirus disease (COVID-19)
O. Fesenko (Slobozhanske, Ukraine), L. Siabro (Dnipro, Ukraine), K. Bielosludtseva (Dnipro, Ukraine)
| |